Obezite: Nedenleri ve tedavi seçenekleri

ZUHAL, BERRİN; ÖZBEK, Elvan

Obezite: Nedenleri ve tedavi seçenekleri

Berrin Zuhal ALTUNKAYNAK, (Atatürk Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Anabilim Dalı, Erzurum, Türkiye)

Elvan ÖZBEK (Atatürk Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Anabilim Dalı, Erzurum, Türkiye)

Van Tıp Dergisi

36 6

Yıl: 2006 Cilt: 13 Sayı: 4 Sayfa Aralığı: 138 - 142 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Obezite: Nedenleri ve tedavi seçenekleri

Öz:

Obezite, genetik ve çevresel etkileşimleri olan; ciddi ve kronik bir hastalıktır. Vücutta normalden fazla miktarda yağ dokusunun olması sebebiyle gelişir, çok sayıda faktöre bağlıdır ve tıbbi tedavi gerektirir. Obezitenin en önemli risk faktörlerini; fiziksel aktivitede azalma, beslenme alışkanlıkları, yaş, cinsiyet, eğitim düzeyi, evlilik, doğum sayısı ve genetik oluşturmaktadır. Kalıtsal olarak da geçebilen obezite özellikle gelişmiş ve gelişmekte olan ülkelerde hızla yayılmaktadır. Ülkemizde toplumun %30'undan fazlası obezdir (erkeklerin % 7.9'u, kadınların %23.4'ü). Birçok kronik hastalığın obeziteyle yakından ilişkili olduğu bilinmektedir. Bu nedenle obezitenin etkenlerinin ve tedavi seçeneklerinin iyi bilinmesi, obezite ve komplikasyonlarının ideal tedavisinin tespit edilebilmesi açısından önemlidir.

Anahtar Kelime: Beslenme bozuklukları Obezite Genetik

Konular: Cerrahi

Obesity: Causes and treatment alternatives

Öz:

Obesity is an important and chronic disease. It occurs due to more body fat accumulation than normal levels. It associates with many factors and it needs to medical treatment. Important risk factors of obesity are feeding habits, sexuality (female), age, education, marriage, labor number and hereditary. Obesity, may be originated from hereditary factors and it progresses very fastly in developed and developing countries. More than 30 % percent of population is obese in Turkey (male %7,9 female %23,4). It is known that obesity is closely related with many chronic disorders. Thus, well knowledge about effects of obesity and its alternative treatments is important for determining ideal treatment of obesity and its complications. Aim of this review is to represent effects causing obesity and its treatment options together.

Anahtar Kelime: Nutrition Disorders Obesity Genetics

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity (Geneva, June, 3–5, 1997). Geneva: WHO.
2. Guyton AC, Hall JE. Textbook of Medical Physiology. İstanbul, Nobel Kitapevi, 2001:797-800.
3. Fox EA, Byerly MS. A mechanism underlying mature-onset obesity: evidence from the hyperphagic phenotype of brain-derived neurotrophic factor mutants. Am J Physiol Regul Integr Comp Physiol, 286: 994-1004, 2004.
4. Killgore WD, Young AD, Femia LA, Bogorodzki P, Rogowska J, Yurgelun-Todd DA. Cortical and limbic activation during viewing of high- versus low-calorie foods. Neuroimage, 19: 1381-1394, 2003.
5. Berthoud HR. Mind versus metabolism in the control of food intake and energy balance. Physiol Behav, 81: 781-793, 2004.
6. King BM, Cook JT, Rossiter KN, Rollins BL. Obesity-inducing amygdala lesions: examination of anterograde degeneration and retrograde transport. Am J Physiol Regul Integr Comp Physiol, 284: 965-982, 2003.
7. Bouchard C. The genetics of human obesity: recent progress. Bull Mem Acad R Med Belg, 156: 455-462, 2001.
8. Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol, 60: 877-883, 2000.
9. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 283: 1544-1548, 1999.
10.Sengier A. Multifactorial etiology of obesity: nutritional and central aspects. Rev Med Brux, 26: 211-214, 2005.
11.Wangensteen T, Undlien D, Tonstad S, Retterstol L. Genetic causes of obesity. Tidsskr Nor Laegeforen, 125: 3090-3093, 2005.
12.Malczewska-Malec M, Wybranska I, Leszczynska-Golabek I, et al. Analysis of candidate genes in Polish families with obesity.Clin Chem Lab Med, 42: 487-493, 2004.
13.Drapeau V, Despres JP, Bouchard C, et al. Modifications in food-group consumption are related to long-term body-weight changes. Am J Clin Nutr, 80: 29-37, 2004.
14.Nelson TL, Vogler GP, Pedersen NL, Hong Y, Miles TP. Genetic and environmental influences on body fat distribution, fasting insulin levels and CVD: are the influences shared? Twin Res, 3:43-50, 2000.
15.Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, et al. Genomewide search for genes influencing percent body fat in Pima Indians suggestive linkage at chromosome 11q21-q22. Pima Diabetes Yine Group. Am J Hum Genet, 60: 166-173, 1997.
16.Green ED, Maffei M, Braden VV, et al. The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res, 5: 5-12, 1995.
17.Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med, 300: 579-584, 1979.
18.Paterson CA. Effects of drugs on the lens. Int Ophthalmol Clin, 11:63-97, 1971.
19.Guy-Grand B. Pharmacological approaches to intervention. Int J Obes Relat Metab Disord, 21: 22-24, 1997.
20.Kramer MS. and Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol, 51: 361-364, 1998.
21.Connolly HM, Crary JL, McGoon MD. et al., Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med, 337: 581-8, 1997.
22.Greenway FL, Smith SR. The future of obesity research. Nutrition, 16: 976-982, 2000.
23.Bray G.A., Blackburn G.L., Ferguson J.M. et al., Sibutramine produces dose-related weight loss. Obes Res, 7:189-198, 1999.
24.Sjostrom L., Rissanen A., Andersen T. et al., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet, 18: 167-172, 1998.
25.National Institutes of Health, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults the evidence report. Obes Res, 6: 51, 1998.
26.Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord, 4: 507-530, 2005.
27.Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol, 16: 297-313, 2005.
28.Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med, 119: 737-743, 1993.
29.Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther, 18: 1006-1035, 1996.
30.Allison DB, Zannolli R, Faith MS, et al. Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies. Int J Obes Relat Metab Disord, 23: 603-611, 1999.
31.Troiano RP, Frongillo EA, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Rel Metab Disord, 20: 63-75, 1996.
32.Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab, 285: 906-916, 2003.
33.Bulucu BZ. Yüksek Lipid İçerikli Diyetin Erişkin Sıçan Karaciğeri Üzerine Etkilerinin Histokimyasal ve Morfometrik Yöntemlerle İncelenmesi. Yüksek Lisans Tezi. Eylül 2003, Atatürk Üniversitesi Sağlık Bilimleri Enstitüsü Histoloji ve Embriyoloji Anabilim Dalı; Erzurum.
34.Erlanson-Albertsson C, York D. Enterostatin––a peptide regulating fat intake. Obes Res, 5: 360-372, 1997.
35.Sanchis D, Balada F, Mar Grasa M. del, et al. Oleoyl-estrone induces the loss of body fat in rats. Int J Obes Relat Metab Disord, 20: 588-594, 1996.
36.Atkinson RL, Dhurandhar NV, Allison DB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes Relat Metab Disord, 29: 281-286, 2005.
37.Dhurandhar NV, Israel BA, Kolesar JM, et al. Transmissibility of adenovirus-induced adiposity in a chicken model. Int J Obes Relat Metab Disord, 25:990-996, 2001.

APA	ZUHAL B, ÖZBEK E (2006). Obezite: Nedenleri ve tedavi seçenekleri. , 138 - 142.
Chicago	ZUHAL BERRİN,ÖZBEK Elvan Obezite: Nedenleri ve tedavi seçenekleri. (2006): 138 - 142.
MLA	ZUHAL BERRİN,ÖZBEK Elvan Obezite: Nedenleri ve tedavi seçenekleri. , 2006, ss.138 - 142.
AMA	ZUHAL B,ÖZBEK E Obezite: Nedenleri ve tedavi seçenekleri. . 2006; 138 - 142.
Vancouver	ZUHAL B,ÖZBEK E Obezite: Nedenleri ve tedavi seçenekleri. . 2006; 138 - 142.
IEEE	ZUHAL B,ÖZBEK E "Obezite: Nedenleri ve tedavi seçenekleri." , ss.138 - 142, 2006.
ISNAD	ZUHAL, BERRİN - ÖZBEK, Elvan. "Obezite: Nedenleri ve tedavi seçenekleri". (2006), 138-142.

APA	ZUHAL B, ÖZBEK E (2006). Obezite: Nedenleri ve tedavi seçenekleri. Van Tıp Dergisi, 13(4), 138 - 142.
Chicago	ZUHAL BERRİN,ÖZBEK Elvan Obezite: Nedenleri ve tedavi seçenekleri. Van Tıp Dergisi 13, no.4 (2006): 138 - 142.
MLA	ZUHAL BERRİN,ÖZBEK Elvan Obezite: Nedenleri ve tedavi seçenekleri. Van Tıp Dergisi, vol.13, no.4, 2006, ss.138 - 142.
AMA	ZUHAL B,ÖZBEK E Obezite: Nedenleri ve tedavi seçenekleri. Van Tıp Dergisi. 2006; 13(4): 138 - 142.
Vancouver	ZUHAL B,ÖZBEK E Obezite: Nedenleri ve tedavi seçenekleri. Van Tıp Dergisi. 2006; 13(4): 138 - 142.
IEEE	ZUHAL B,ÖZBEK E "Obezite: Nedenleri ve tedavi seçenekleri." Van Tıp Dergisi, 13, ss.138 - 142, 2006.
ISNAD	ZUHAL, BERRİN - ÖZBEK, Elvan. "Obezite: Nedenleri ve tedavi seçenekleri". Van Tıp Dergisi 13/4 (2006), 138-142.